Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed
A Double-masked, Placebo-controlled Study With Open Label Period to Evaluate MEDI-551 in Neuromyelitis Optica and Neuromyelitis Optica Spectrum Disorders
Warner Chilcott sells Vectrin product line to Medicis
MHC-restricted depletion of human myelin basic protein-reactive T cells by T cell vaccination.
CD200-CD200R1 interaction contributes to neuroprotective effects of anandamide on experimentally induced inflammation.
What to expect after natalizumab cessation in a real-life setting.
Clinical and paraclinical findings in natalizumab-associated infratentorial progressive multifocal leukoencephalopathy patients.
Effects of phenytoin on the persistent Na+ current of mammalian CNS neurones.
Treatment of HIV and Risk of Multiple Sclerosis.
Cyclophosphamide so-so verdict in progressive MS
Fingolimod (FTY720) stimulates ca(2+)/calcineurin signaling in fission yeast.
Nabilone as an Adjunctive to Gabapentin for Multiple Sclerosis-Induced Neuropathic Pain: A Randomized Controlled Trial.
Epidemiology of neuromyelitis optica in the world: a systematic review and meta-analysis.
Increase in the prevalence of multiple sclerosis over a 17-year period in Osona, Catalonia, Spain.
Structure of the first sphingosine 1-phosphate receptor.
MSQoL-54 predicts change in fatigue after inpatient rehabilitation for people with multiple sclerosis.
A2A Adenosine Receptor Signaling in Lymphocytes and the Central Nervous System Regulates Inflammation during Experimental Autoimmune Encephalomyelitis.
Galectin-1 deactivates classically activated microglia and protects from inflammation-induced neurodegeneration.
Age-Dependent Seroprevalence of JCV Antibody in Children.
[Central motor pathways in children with multiple sclerosis].
Selective depression of low-release probability excitatory synapses by sodium channel blockers.
Distinct serum cytokine profiles in neuromyelitis optica and multiple sclerosis.
Complex molecular and functional outcomes of single versus sequential cytokine stimulation of rat microglia.
Dalfampridine improves walking speed, walking endurance, and community participation in veterans with multiple sclerosis: a longitudinal cohort study.
Metabolism and disposition in humans of raltegravir (MK-0518), an anti-AIDS drug targeting the human immunodeficiency virus 1 integrase enzyme.
Multiple neuroprotective mechanisms of minocycline in autoimmune CNS inflammation.
Pages
« first
‹ previous
…
202
203
204
205
206
207
208
209
210
…
next ›
last »